CN102731484B - Preparation method for prodigiosins analogue - Google Patents
Preparation method for prodigiosins analogue Download PDFInfo
- Publication number
- CN102731484B CN102731484B CN201210201792.XA CN201210201792A CN102731484B CN 102731484 B CN102731484 B CN 102731484B CN 201210201792 A CN201210201792 A CN 201210201792A CN 102731484 B CN102731484 B CN 102731484B
- Authority
- CN
- China
- Prior art keywords
- analogue
- pyrrole
- prodigiosin
- mmol
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 150000003233 pyrroles Chemical class 0.000 claims abstract description 26
- 238000000605 extraction Methods 0.000 claims abstract description 18
- 239000002841 Lewis acid Substances 0.000 claims abstract description 6
- 150000007517 lewis acids Chemical class 0.000 claims abstract description 6
- 150000002466 imines Chemical class 0.000 claims abstract description 5
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract description 4
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 3
- 238000005406 washing Methods 0.000 claims abstract description 3
- TWFGRJUTAULJPZ-USZBIXTISA-N prodigiosin Chemical class N1=C(C)C(CCCCC)=C\C1=C/C1=NC(C=2[N]C=CC=2)=C[C]1OC TWFGRJUTAULJPZ-USZBIXTISA-N 0.000 claims description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 19
- MFFMQGGZCLEMCI-UHFFFAOYSA-N 2,4-dimethyl-1h-pyrrole Chemical compound CC1=CNC(C)=C1 MFFMQGGZCLEMCI-UHFFFAOYSA-N 0.000 claims description 16
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims description 16
- PAPNRQCYSFBWDI-UHFFFAOYSA-N DMP Natural products CC1=CC=C(C)N1 PAPNRQCYSFBWDI-UHFFFAOYSA-N 0.000 claims description 14
- -1 isoindole aldehyde Chemical class 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 229960001701 chloroform Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 33
- 238000006243 chemical reaction Methods 0.000 abstract description 28
- 238000003786 synthesis reaction Methods 0.000 abstract description 24
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- IMYJEZMJKCOABR-UHFFFAOYSA-N 2h-isoindole-1-carbaldehyde Chemical compound C1=CC=CC2=C(C=O)NC=C21 IMYJEZMJKCOABR-UHFFFAOYSA-N 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000003760 magnetic stirring Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 28
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 230000005526 G1 to G0 transition Effects 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 238000004440 column chromatography Methods 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 14
- 229910052786 argon Inorganic materials 0.000 description 14
- HCOLPNRPCMFHOH-UHFFFAOYSA-N Prodigiosin Natural products CCCCCC1C=C(C=C/2N=C(C=C2OC)c3ccc[nH]3)N=C1C HCOLPNRPCMFHOH-UHFFFAOYSA-N 0.000 description 13
- 239000000975 dye Substances 0.000 description 7
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 6
- 0 Cc1c(C(c2c3c(*)c(C)c(C)c2II)=NC3=C(*)c2c(*)c(*)c(*)[n]2)[n]c(*)c1* Chemical compound Cc1c(C(c2c3c(*)c(C)c(C)c2II)=NC3=C(*)c2c(*)c(*)c(*)[n]2)[n]c(*)c1* 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- JPNHCPHNENLSRX-UHFFFAOYSA-N 1-(5-chloroisoindol-2-yl)ethanone Chemical compound ClC1=CC2=CN(C=C2C=C1)C(C)=O JPNHCPHNENLSRX-UHFFFAOYSA-N 0.000 description 2
- TXKQBYYDTLOLHA-UHFFFAOYSA-N 3-methoxy-1,2-dihydropyrrol-5-one Chemical compound COC1=CC(=O)NC1 TXKQBYYDTLOLHA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 1
- VGZCKCJMYREIKA-UHFFFAOYSA-N 1-(2,4-dimethyl-1h-pyrrol-3-yl)ethanone Chemical compound CC(=O)C=1C(C)=CNC=1C VGZCKCJMYREIKA-UHFFFAOYSA-N 0.000 description 1
- FYXXJXKLTCPPHW-UHFFFAOYSA-N 2-methoxy-1h-pyrrole Chemical group COC1=CC=CN1 FYXXJXKLTCPPHW-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- AKWXPKHCAOCUDA-NHDPSOOVSA-N CC(c1c(C)[nH]c(/C=C(/c2c3cccc2)\N=C3c2c(C)c(C(C)=O)c(C)[nH]2)c1C)O Chemical compound CC(c1c(C)[nH]c(/C=C(/c2c3cccc2)\N=C3c2c(C)c(C(C)=O)c(C)[nH]2)c1C)O AKWXPKHCAOCUDA-NHDPSOOVSA-N 0.000 description 1
- AOSAVBQEIUERAG-NVNXTCNLSA-N CC(c1c(C)[nH]c(/C=C(/c2ccccc22)\N=C2Cl)c1C)=O Chemical compound CC(c1c(C)[nH]c(/C=C(/c2ccccc22)\N=C2Cl)c1C)=O AOSAVBQEIUERAG-NVNXTCNLSA-N 0.000 description 1
- LUQUIZCNANEHMJ-ODLFYWEKSA-N CC(c1c(C)[nH]c(/C=C2\N=C(c3ccc[nH]3)c3c2cccc3)c1C)=O Chemical compound CC(c1c(C)[nH]c(/C=C2\N=C(c3ccc[nH]3)c3c2cccc3)c1C)=O LUQUIZCNANEHMJ-ODLFYWEKSA-N 0.000 description 1
- QOEZCKVOZGBJCY-ZROIWOOFSA-N Cc1c(/C=C(/C=C2)\N=C2c2c(C)cc(C)[nH]2)[nH]c(C)c1 Chemical compound Cc1c(/C=C(/C=C2)\N=C2c2c(C)cc(C)[nH]2)[nH]c(C)c1 QOEZCKVOZGBJCY-ZROIWOOFSA-N 0.000 description 1
- KTWWAJNTNIEREY-ZSOIEALJSA-N Cc1c(/C=C(/c2c3cccc2)\N=C3Cl)[nH]c(C)c1 Chemical compound Cc1c(/C=C(/c2c3cccc2)\N=C3Cl)[nH]c(C)c1 KTWWAJNTNIEREY-ZSOIEALJSA-N 0.000 description 1
- UGZNHSNGQZKOHV-XKZIYDEJSA-N Cc1c(/C=C(/c2c3cccc2)\N=C3c2c(C)c(cccc3)c3[nH]2)[nH]c(C)c1 Chemical compound Cc1c(/C=C(/c2c3cccc2)\N=C3c2c(C)c(cccc3)c3[nH]2)[nH]c(C)c1 UGZNHSNGQZKOHV-XKZIYDEJSA-N 0.000 description 1
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N Cc1c[nH]c2ccccc12 Chemical compound Cc1c[nH]c2ccccc12 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- QWGXLWQDOWTWCG-UHFFFAOYSA-N O=Cc([nH]1)ccc1Cl Chemical compound O=Cc([nH]1)ccc1Cl QWGXLWQDOWTWCG-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229950006584 obatoclax Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 229940074386 skatole Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003911 water pollution Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Landscapes
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
Abstract
The present invention relates to a preparation method for a prodigiosins analogue, wherein the method comprises: adopting 3-halogenated pyrrole or isoindolealdehyde or an imine compound and an pyrrole derivative as raw materials, wherein a molar ratio is 1:10-100; carrying out a reaction in an organic solvent for 1-24 hours at a temperature of 20-80 DEG C under magnetic stirring and a condition of Lewis acid; carrying out extraction, water washing, drying, and reduced pressure concentration; and carrying out silica gel column chromatography separation to obtain the prodigiosins analogue. Compared with the method in the prior art, the method of the present invention has the following advantages that: the process is simple, the synthesis efficiency is high, and the foundation is established for large scale industrial productions of prodigiosins and analogues thereof.
Description
Technical field:
The present invention relates to a kind of preparation method of prodigiosin analogue, belong to organic chemical industry and technical field of fine.
Background technology:
Prodigiosin (Prodigiosins, be called for short PG) and analogue be a class containing the natural pigment of methoxypyrrole skeleton structure, it is the secondary metabolite of some actinomycetes, husky thunder bacterium and other bacteriums, having very strong antitumor, antibacterium, antimycotic, the multiple biological activity such as anti-malarial and immunosuppression, is the potential cancer-resisting substance of a class.Recent study finds that prodigiosin has autoimmunity depression activity and has resistance effect to the various human such as adenocarcinoma of lung, prostate cancer cancer cells, under identical Dosages, to normal cell without any toxic action.
Prodigiosin and analogue thereof have become the extremely potential PTS of one.Prodigiosin can the apoptosis of inducing cancer cell in addition, under extremely low concentration, can kill the most of planktonic organism causing red tide fast, in the improvement of water pollution, demonstrate huge power.Research shows; natural pigment prodigiosin has good dye uptake and anti-microbial property on the fabrics such as silk, wool, modified acryl fibre; up-to-date research shows that prodigiosin and analogue thereof also can be used as ultraviolet protective material, and therefore prodigiosin can be used as the dyestuff of multifunction environment-protection type or dye additive is applied to dyeing.It can keep the long period in sour environment, can transport Cl in human body
-(Chem. Commun. 2005,30,5781-5783.; Chem.Commun. 2005,30,3773-3775.) and cause Cu
2+inducing DNA double bond cracking etc. (Chem Res Toxicl, 2002,15,2480-2486).
The PG cytotoxic properties of different structure is different.The difference replacement of PGC-6 methoxyl group also can have an impact to its effect, and when it is replaced by the alkoxyl group more grown, activity can decline.Define new PG derivative according to the molecular modification that these achievements in research are carried out, its activity index exceeds several times (Chembiochem. 2001,2,60-68) than parent molecule.Wherein the prodigiosin derivative Obatoclax of synthetic has entered the clinical class I/II phase as kinds cancer medicine and has studied (Chem. Eur. J. 2011,17,14074).Its another analogue PNU-156804 presents than prodigiosin and the higher immunosuppressive activity of analogue thereof and lower toxicity (J. Med. Chem. 2000,43,2557).Therefore the research of prodigiosin derivative and analogue has broad application prospects in fields such as cancer therapy.
The sixties in 20th century is early stage, and first passage is complete synthesis obtains prodigiosin in Rapoport seminar (J. Am. Chem. Soc. 1962,84,635-642), has started the beginning that prodigiosin is complete synthesis.The whole process of experiment is divided into four steps, but more complicated and difficulty.Seminar (Synlett, 1996,6,513-514 such as D ' Alessio and Dairi; Patent WO 97/30029; Tetrahedron Lett, 2006,47,2605-2606) propose the scheme of new preparation PG analogue according to tripyrrole precursor structure three kinds of different fracture modes: (1) first C ring is connected with B ring be then coupled by Suzuki close with A loops again (simulate biosynthesizing route is first be connected with A ring by B ring in the past) PG precursor substance, combined coefficient improves, but can not be used for the undecyl PG of synthesis of natural; (2) commercial 4-methoxy-3-Pyrrolin-2-one is utilized to obtain prodigiosin derivative and analogue precursor 4-methoxy-2 thereof through two-step reaction, 2'-bipyrrole-5-carboxaldehyde, is then coupled different pyrroles and derivative thereof from it and obtains different PG derivatives and analogue.
Although achieve certain achievement about the chemosynthesis research of prodigiosin and analogue thereof, chemical synthesis fails to prepare prodigiosin derivative and analogue in a large number always.The method of current existing synthesis prodigiosin derivative, step is complicated, and needs the Suzuki coupling of using precious metal palladium catalysis, substrate restricted application.
Summary of the invention:
The invention provides a kind of synthetic method of novel simplification, namely synthesized the method for prodigiosin derivative and analogue thereof by Lewis acid, improve combined coefficient, for prodigiosin and analogue industrial mass production lay the foundation.
The 3-halogenated pyrrole of different substituents or isoindole aldehyde or imine compound and pyrrole derivatives make raw material, their mol ratio is 1:10-100, in organic solvent, under magnetic agitation, under temperature 20 DEG C ~ 80 DEG C conditions, under Lewis acid condition, react 1 ~ 24 hour, through extraction, washing, drying, concentrating under reduced pressure, then be separated obtained prodigiosin analogue through silica gel column chromatography.
Described organic solvent is selected from methylene dichloride, trichloromethane, 1,2-methylene dichloride.
Described Lewis acid is selected from POCl
3, CH
3cOOH, CH
3sO
3h, CF
3sO
3h.
In described raw material, 3-halogenated pyrrole or isoindole aldehyde or imine compound molecular structure are as general formula V, VI:
X=Cl, Br, I, CF in general formula A
3sO
3; Y, Z with define in general formula I identical; R
8=R
9=H, C
1-12straight chain or branched-chain alkyl, C
1-12cycloalkyl, (CH
2)
mo(CH
2)
nh.
The general structure of the prodigiosin derivative that the present invention is made and analogue is I:
In general formula I: Y, Z are H, C
1-12alkyl, cycloalkyl ,-CHCH-,-CR
8cR
9-, phenyl, Cl, Br, I, OR
8, NR
8r
9, CN, (CH=CH
2) (C
6h
4) R
8, (CH
2)
mo(CH
2)
nh, (CH
2)
ncOOM, (CH
2)
mcOM or (CH
2)
msO
3m; R
4=H, CH
3, aryl; R
1, R
2, R
3, R
5, R
6, R
7for H, C
1-12alkyl, cycloalkyl, phenyl, naphthyl, F, Cl, Br, I, OR
8, NR
8r
9, CN, (CH=CH
2) (C
6h
4) R
8, (CH
2)
mo(CH
2)
nh, (CH
2)
ncOOM, (CH
2)
mcOM or (CH
2)
msO
3m; R
8=R
9=H, C
1-12straight chain or branched-chain alkyl, C
1-12cycloalkyl, (CH
2)
mo(CH
2)
nh; N, m=0 – 15; M=H, Li, Na, K, NH
4.
In said structure general formula, the preferred structure of prodigiosin derivative and analogue is formula II, III and IV:
In general formula I I,
R
4during for H,
R
1, R
2, R
3, R
4, R
5, R
6, R
7be H;
R
1, R
3, R
5, R
7for CH
3, R
2, R
4, R
6for H;
R
1, R
3, R
5, R
7for CH
3, R
2, R
4, R
6for CH
2cH
3;
R
4for CH
3time,
R
1, R
2, R
3, R
4, R
5, R
6, R
7be H;
R
1, R
3, R
5, R
7for CH
3, R
2, R
4, R
6for H;
R
1, R
3, R
5, R
7for CH
3, R
2, R
4, R
6for CH
2cH
3;
R
1, R
3for CH
3, R
2, R
4, R
5, R
6, R
7be H;
In general formula III, IV,
R
1, R
3, R
5, R
7for CH
3, R
2, R
4, R
6for H;
R
1, R
3, R
5, R
7for CH
3, R
2, R
4, R
6for CH
2cH
3;
The present invention compared with prior art, has that technique is simple, combined coefficient is high, for prodigiosin and analogue industrial mass production lay the foundation.
Accompanying drawing explanation
Fig. 1 is the X-ray single crystal diffraction structure iron of product IIj.
Fig. 2 is the X-ray single crystal diffraction structure iron of product IIIa.
Embodiment
Below in conjunction with case study on implementation, the invention will be further described.
Embodiment 1:
The syntheses and properties of Compound II per a:
Method one:
In 50ml round-bottomed flask, under argon shield, add 20 ml CH
2cl
2, add pyrroles (0.69 ml, 10 mmol) and 5-chloro-2-aldehyde isoindole (90 mg, 0.5 mmol) respectively, and add the POCl be dissolved in 1 ml methylene dichloride fast
3(470 l, 5 mmol), after reacting 16 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 4/1 with ethyl acetate volume ratio) and obtain yellow powder, productive rate is 61% (79 mg).
Method two:
In 50ml round-bottomed flask, under argon shield, add 20 ml CH
2cl
2, add pyrroles (0.69 ml, 10 mmol) and 5-chloro-2-imines isoindole (125 mg, 0.5 mmol) respectively, and add POCl
3(470 l, 5 mmol), after back flow reaction 5 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 4/1 with ethyl acetate volume ratio) and obtain yellow powder, productive rate is 56% (72 mg).
1H NMR (300 MHz, CDCl
3): δ 11.52(s, 1H), 10.07(s, 1H), 8.03(d, J = 7.2 Hz, 1H), 7.83(d, J = 7.2 Hz, 1H), 7.45-7.40(m, 2H), 7.23-6.97(m, 3H), 6.60(s, 1H), 6.41(s, 1H), 6.25(s, 1H).
13C NMR (75 MHz, CDCl
3): δ 157.1, 143.7, 142.0, 134.6, 130.7, 128.4, 127.1, 126.8, 124.6, 122.8, 122.3, 119.5, 117.1, 114.0, 113.8, 111.3, 110.6. HRMS (EI) Calcd. for C
17H
13N
3 [M]
+: 259.1109, found 259.1112.
Embodiment 2:
The syntheses and properties of Compound II per b:
Method one:
In 50ml round-bottomed flask, under argon shield, add 20 ml CH
2cl
2, add pyrroles (0.5 ml, 5 mmol) and 5-chloro-2-aldehyde isoindole (90 mg, 0.5 mmol) respectively, and add the POCl be dissolved in 1 ml methylene dichloride fast
3(470 l, 5 mmol), after reacting 2 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 4/1 with ethyl acetate volume ratio) and obtain red powder, productive rate is 75% (118 mg).
Method two:
In 50ml round-bottomed flask, under argon shield, add 20 ml CH
2cl
2, add pyrroles (0.5 ml, 5 mmol) and 5-chloro-2-imines isoindole (125 mg, 0.5 mmol) respectively, and add POCl
3(470 l, 5 mmol), after back flow reaction 2 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 4/1 with ethyl acetate volume ratio) and obtain red powder, productive rate is 78% (123 mg).
1H NMR (300 MHz, CDCl
3): δ 8.73(s, 1H), 7.87-7.82(m, 2H), 7.42(d, J = 7.2 Hz, 1H), 7.34(d, J = 7.2 Hz, 1H), 7.06(s, 1H), 6.01 (s, 1H), 5.86 (s, 1H), 2.58 (s, 3H), 2.34(s, 3H), 2.31(s, 6H).
13C NMR (75 MHz, CDCl
3): δ 155.3, 142.3, 141.9, 135.4, 134.9, 131.3, 128.1, 127.9, 127.2, 125.2, 124.3, 124.1, 121.7, 119.2, 112.1, 111.2, 110.9, 14.3, 13.6, 13.3, 11.4. HRMS (EI) Calcd. for C
21H
21N
3 [M]
+: 315.1735, found 315.1731.
Case study on implementation 3:
The syntheses and properties of Compound II per c:
2,4-dimethyl pyrrole is made into 2, the 4-dimethyl-3-N-ethyl pyrrole N-s that mole number is identical, other are with embodiment 2 method one, and productive rate is 73% (135 mg).
Method two:
2,4-dimethyl pyrrole is made into 2, the 4-dimethyl-3-N-ethyl pyrrole N-s that mole number is identical, other are with embodiment 2 method two, and productive rate is 76% (141 mg).
1H NMR (300 MHz, CDCl
3): δ 8.40(s, 1H), 7.85-7.80(m, 2H), 7.38-7.30(m, 2H), 7.04(s, 1H), 2.53-2.24(m, 16H), 1.19-1.08(m, 6H).
13C NMR (75 MHz, CDCl
3): δ 154.7, 142.4, 141.8, 134.9, 132.3, 127.6, 127.3, 127.1, 125.3, 124.0, 123.4, 122.4, 121.6, 119.2, 111.0, 17.6, 17.6, 15.6, 15.5, 11.9, 11.7, 9.6. HRMS (EI) Calcd. for C
25H
29N
3 [M]
+: 371.2361, found 371.2359.
Embodiment 4:
The syntheses and properties of Compound II per d:
Method one:
2,4-dimethyl pyrrole is made into 2,4-dimethyl-3-acetyl pyrrole, elutriant to be sherwood oil and ethyl acetate volume ratio be 2/1 mixed system cross post, other are with embodiment 2 method one, and productive rate is 57% (114 mg).
Method two:
2,4-dimethyl pyrrole is made into 2, the 4-dimethyl-3-acetyl pyrroles that mole number is identical, elutriant to be sherwood oil and ethyl acetate volume ratio be 2/1 mixed system cross post, other are with embodiment 2 method two, and productive rate is 60% (120 mg).
1H NMR (300 MHz, CDCl
3): δ11.99(s, 1H), 11.77(s, 1H), 8.04(s, 1H), 7.85(s, 1H), 7.44-7.42(m, 3H), 2.62-2.41(m, 18H).
13C NMR (75 MHz, CDCl
3): δ194.4, 194.1, 157.5, 144.7, 141.8, 141.1, 139.1, 135.6, 128.4, 128.1, 127.9, 126.7, 124.3, 123.9, 123.5, 123.3, 120.5, 112.3, 96.4, 31.8, 31.7, 16.2, 15.4, 14.8, 12.8. HRMS (EI) Calcd. for C
25H
25N
3O
2 [M]
+: 399.1947, found 399.1949.
Embodiment 5:
The syntheses and properties of Compound II per e:
Method one:
In 50ml round-bottomed flask, under argon shield, add 20 ml CH
2cl
2, add pyrroles (0.69 ml, 10 mmol) and 5-chloro-2-ethanoyl isoindole (97 mg, 0.5 mmol) respectively, and add the POCl be dissolved in 1 ml methylene dichloride fast
3(470 l, 5 mmol), react 16 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 4/1 with ethyl acetate volume ratio) and obtain red powder, productive rate is 78% (106 mg).
Method two:
In 50ml round-bottomed flask, under argon shield, add 20 ml CH
2cl
2, add pyrroles (0.69 ml, 10 mmol) and 5-chloro-2-imines isoindole (125 mg, 0.5 mmol) respectively, and add POCl
3(470 l, 5 mmol), back flow reaction 5h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 4/1 with ethyl acetate volume ratio) and obtain red powder, productive rate is 73% (100 mg).
1H NMR (300 MHz, CDCl
3): δ 12.53(s, 1H), 9.32(s, 1H), 8.03-7.98(m, 2H), 7.44-7.35(m, 2H), 7.14-7.10(m, 2H), 6.77(s, 1H), 6.45(s, 1H), 6.33(s, 1H), 2.75(s, 3H).
13C NMR (75 MHz, CDCl
3): δ 154.0, 142.9, 140.9, 135.4, 134.7, 129.2, 128.0, 127.3, 125.9, 123.8, 123.6, 122.2, 121.4, 114.4, 112.2, 111.1, 110.1, 17.5. HRMS (EI) Calcd. for C
18H
15N
3[M]
+: 273.1266, found 273.1269.
Embodiment 6:
The syntheses and properties of Compound II per f:
Method one:
In 50ml round-bottomed flask, under argon shield, add 20 ml CH
2cl
2, add 2,4-dimethyl pyrrole (0.5 ml, 5 mmol) and 5-chloro-2-ethanoyl isoindole (97 mg, 0.5 mmol) respectively, and add the POCl be dissolved in 1 ml methylene dichloride fast
3(470 l, 5 mmol), back flow reaction 2 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 4/1 with ethyl acetate volume ratio) and obtain red powder, productive rate is 79% (130 mg).
Method two:
In 50ml round-bottomed flask, under argon shield, add 20 ml CH
2cl
2, add 2,4-dimethyl pyrrole (0.5 ml, 5 mmol) and 5-chloro-2-imines isoindole (125 mg, 0.5 mmol) respectively, and add POCl
3(470 l, 5 mmol), back flow reaction 2 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 4/1 with ethyl acetate volume ratio) again and obtain red powder, productive rate 79% (130 mg).
1H NMR (300 MHz, CDCl
3): δ 13.25(s, 1H), 8.40(s, 1H), 8.02(d, J = 7.5 Hz, 1H), 7.83(d, J = 7.5 Hz, 1H), 7.39(t, J = 7.2, 1H), 7.31(t, J = 7.2Hz, 1H), 6.00(s, 1H), 5.83(s, 1H), 2.84(s, 3H), 2.53(s, 3H), 2.38(s, 3H), 2.31(s, 3H).
13C NMR (75 MHz, CDCl
3): δ 151.8, 141.8, 140.7, 135.5, 133.7, 131.8, 130.5, 129.5, 127.6, 127.2, 124.9, 123.9, 123.6, 123.0, 121.7, 113.3, 111.5, 18.1, 16.5, 14.0, 13.5. HRMS (EI) Calcd. for C
22H
23N
3 [M]
+: 329.1892, found 329.1887.
Embodiment 7:
The syntheses and properties of Compound II per g:
Method one:
2,4-dimethyl pyrrole is made into 2, the 4-dimethyl-3-N-ethyl pyrrole N-s that mole number is identical, other are with embodiment 6 method one, and productive rate is 72% (138 mg).
Method two:
2,4-dimethyl pyrrole is made into 2, the 4-dimethyl-3-N-ethyl pyrrole N-s that mole number is identical, other are with embodiment 6 method two, and productive rate is 65% (125 mg).
1H NMR (300 MHz, CDCl
3): δ 13.23(s, 1H), 8.27(s, 1H), 8.04(d, J = 7.8 Hz, 1H), 7.86(d, J = 7.5 Hz, 1H), 7.40(t, J = 7.2 Hz, 1H), 7.31(t, J = 7.2 Hz, 1H), 2.89(s, 3H), 2.58-2.32(m, 16H), 1.19(t, J = 7.5 Hz, 3H), 1.11(t, J = 7.5 Hz, 3H).
13C NMR (75 MHz, CDCl
3): δ 151.8, 142.0, 140.8, 135.6, 131.6, 131.1, 129.1, 127.1, 126.9, 125.2, 124.9, 124.7, 124.1, 123.6, 123.1, 121.9, 121.3, 18.5, 17.7, 17.5, 15.9, 15.7, 13.5, 11.8, 11.8, 11.7. HRMS (EI) Calcd. for C
26H
31N
3 [M]
+: 385.2518, found 385.2520.
Embodiment 8:
The syntheses and properties of Compound II per h:
In 50ml round-bottomed flask, under argon shield, add 20 ml CH
2cl
2, add pyrroles (0.69 ml, 10mmol) and chloro-7,9-dimethylbiphenyl two pyrroles of 1-(128 mg, 0.5 mmol) respectively, and add POCl fast
3(470 l, 5 mmol), room temperature reaction 12 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 4/1 with ethyl acetate volume ratio) again and obtain green powder, productive rate 87% (125 mg).
1H NMR (300 MHz, CDCl
3): δ 10.38(s, 1H), 8.04(d, J = 7.2 Hz, 1H), 7.87(d, J = 7.2 Hz, 1H), 7.45-7.38(m, 2H), 7.17-7.13(m, 2H), 6.90(s, 1H), 6.37(s, 1H), 5.78(s, 1H), 2.27(s, 3H), 2.08(s, 3H).
13C NMR (75 MHz, CDCl
3): δ 155.6, 142.5, 140.3, 137.2, 134.1, 129.7, 127.8, 127.5, 127.1, 126.0, 122.5, 122.3, 119.1, 113.1, 112.0, 111.7, 110.9, 12.8, 11.6. HRMS (EI) Calcd. for C
19H
17N
3 [M]
+: 287.1422, found 287.1419.
Embodiment 9:
The syntheses and properties of Compound II per i:
Chloro-for 1-7,9-dimethylbiphenyl two pyrroles are made into chloro-7, the 9-dimethyl-8-ethyl benzodipyrroles of 1-, and other are with embodiment 9, and productive rate is 85% (134 mg).
1H NMR (300 MHz, CDCl
3): δ10.13(s, 1H), 8.02(d, J = 7.5 Hz, 1H), 7.86(d, J = 7.5 Hz, 1H), 7.43(t, J = 7.2 Hz, 1H), 7.36(d, J = 7.2 Hz, 1H), 7.15(s, 1H), 7.10(s, 1H), 6.94(s, 1H), 6.38(s, 1H), 2.36(q, J = 7.5 Hz, 2H), 2.22(s, 3H), 2.10(s, 3H), 1.05(t, J = 7.5, 3H).
13C NMR (75 MHz, CDCl
3): δ154.7, 142.2, 133.9, 127.7, 127.5, 126.5, 125.9, 125.7, 124.3, 122.0, 121.9, 119.0, 112.6, 112.3, 112.0, 111.4, 110.9, 17.5, 15.4, 11.4, 9.7. HRMS (EI) Calcd. for C
21H
21N
3 [M]
+: 315.1735, found 315.1732.
Embodiment 10:
The syntheses and properties of Compound II per j:
Chloro-for 1-7,9-dimethylbiphenyl two pyrroles are made into chloro-7, the 9-dimethyl-8-ethanoyl benzodipyrroles of 1-, and other are with embodiment 9, and productive rate is 78% (60 mg).
1H NMR (300 MHz, CDCl
3): δ12.19(s, 1H), 11.69(s, 1H), 8.17-8.11(m, 2H), 7.48-7.29(m, 6H), 6.39(s, 1H), 2.49-2.44(m, 9H).
13C NMR (75 MHz, CDCl
3): δ195.3, 156.7, 144.7, 142.4, 142.3, 135.2, 128.9, 128.2, 127.9, 127.7, 124.3, 123.5, 122.9, 121.0, 114.3, 111.8, 111.7, 32.2, 16.4, 13.1. HRMS (EI) Calcd. for C
21H
19N
3O
[M]
+: 329.1528, found 329.1534.
Fig. 1 is the single crystal diffraction figure of Compound II per j, and made by the structure of single crystal diffraction to compound and accurately having pointed out, crystalline structure shows this compound and possesses higher level conjugacy.
Embodiment 11:
The syntheses and properties of Compound II per k:
Pyrroles is made into 2,4-identical dimethyl-3-N-ethyl pyrrole N-s of mole number, and other are with embodiment 9, and productive rate is 89% (76 mg).
1H NMR (300 MHz, CDCl
3): δ 8.39(s, 1H), 7.85-7.80(m, 2H), 7.39(d, J = 6 Hz, 1H), 7.31(d, J = 6 Hz, 1H), 7.03(s, 1H), 5.84(s, 1H), 2.53-2.28(m, 14H), 1.16(t, J = 6 Hz, 3H).
13C NMR (75 MHz, CDCl
3): δ 155.3, 142.6, 141.8, 135.1, 128.3, 127.9, 127.6, 127.2, 125.5, 124.6, 123.2, 122.7, 121.7, 119.3, 110.9, 110.8, 17.6, 15.6, 13.7, 12.0, 11.7, 11.5. HRMS (EI) Calcd. for C
23H
25N
3 [M]
+: 343.2048, found 343.2054.
Embodiment 12:
The syntheses and properties of Compound II per l:
Pyrroles is made into the identical 3-skatole of mole number, and other are with embodiment 9; Back flow reaction 15 h, after reaction terminates, extraction, drying, concentrating under reduced pressure obtains thick product, then (stationary phase is silica gel through column chromatography, elutriant is sherwood oil is the mixed system of 4/1 with ethyl acetate volume ratio) be separated and obtain red powder, productive rate is 76% (90 mg).
1H NMR (300 MHz, CDCl
3): δ 8.49(s, 1H), 7.87(d, J = 7.8 Hz, 1H), 7.83(d, J = 7.8 Hz, 1H), 7.69(d, J = 7.8 Hz, 1H), 7.43-7.16(m, 5H), 7.11(s, 1H), 5.88(s, 1H), 2.73(s, 3H), 2.34(s, 3H), 2.29(s, 3H).
13C NMR (75 MHz, CDCl
3): δ 155.3, 142.2, 141.5, 137.1, 136.9, 135.0, 130.0, 129.9, 128.4, 127.4, 125.7, 123.9, 121.8, 120.0, 119.7, 119.2, 114.8, 113.8, 111.6, 111.3, 13.9, 11.5, 11.1. HRMS (EI) Calcd. for C
24H
21N
3 [M]
+: 351.1735, found 351.1742.
Embodiment 13:
The syntheses and properties of Compound II per m:
Pyrroles is made into the identical indoles of mole number, and reflux 15 h, and other are with embodiment 9, and productive rate is 51% (86 mg).
1H NMR (300 MHz, CDCl
3): δ 11.8(s, 1H), 8.60(s, 1H), 8.48(s, 1H), 7.94-7.83(m, 3H), 7.41-7.31(m, 5H), 7.12(s, 1H), 5.88(s, 1H), 2.40(s, 3H), 2.31(s, 3H).
13C NMR (75 MHz, CDCl
3): δ 158.7, 143.0, 141.6, 136.7, 135.8, 135.5, 128.4, 128.1, 127.5, 126.6, 126.5, 125.9, 123.7, 122.3, 121.7, 121.7, 119.3, 113.4, 112.0, 111.8, 111.0, 13.9, 11.6. HRMS (EI) Calcd. for C
23H
19N
3 [M]
+: 337.1579, found 337.1578.
Embodiment 14:
The syntheses and properties of compound III a:
Method one:
In 50ml round-bottomed flask, under argon shield, add 20 ml CH
2cl
2, add 2,4-dimethyl pyrrole (0.5 ml, 5 mmol) and 3-methoxyl group-5-chloro-2-aldehyde pyrroles (102 mg, 0.5 mmol) respectively, and add the POCl be dissolved in 1 ml methylene dichloride fast
3(470 l, 5 mmol), back flow reaction 8 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 5/2 with ethyl acetate volume ratio) and obtain red-purple pressed powder dyestuff, productive rate is 43% (64 mg).
Method two:
In 50ml round-bottomed flask, under argon shield, add 20 ml ClCH
2cH
2cl, adds 2,4-dimethyl pyrrole (0.5 ml, 5 mmol) and 3-methoxyl group-5-chloro-2-imines pyrroles (102 mg, 0.5 mmol) respectively, and adds POCl
3(470 l, 5 mmol), back flow reaction 6 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 5/2 with ethyl acetate volume ratio) and obtain red-purple pressed powder dyestuff, productive rate is 38% (56 mg).
1H NMR (300 MHz, CDCl
3): δ 12.51(s, 1H), 12.03(s, 1H), 6.92(s, 1H), 6.04-5.90(m, 3H), 4.01(s, 3H), 2.54(s, 3H), 2.41(s, 3H), 2.33(s, 3H), 2.27(s, 3H).
13C NMR (75 MHz, CDCl
3): δ 169.4, 158.9, 138.7, 136.2, 133.1, 130.5, 126.5, 124.5, 124.2, 116.2, 114.2, 111.6, 95.7, 58.5, 13.8, 12.3, 12.1, 11.6. HRMS (EI) Calcd. for C
18H
21N
3O
[M]
+: 295.1685, found 295.1682.
Fig. 2 is the single crystal diffraction figure of compound III a, has been made accurately pointing out by the structure of single crystal diffraction to compound, due to the impact of methyl steric hindrance, causes 2,4-dimethyl pyrrole five-ring place plane and two faces, pyrroles's methine place to be departed from a little.
Embodiment 15:
The syntheses and properties of compound III b:
Method one:
2,4-methylpyrrole is made into 2,4-dimethyl-3-N-ethyl pyrrole N-, and other are with embodiment 14 method one, and productive rate is 41% (72 mg).
Method two:
2,4-methylpyrrole is made into 2,4-dimethyl-3-N-ethyl pyrrole N-, and other are with embodiment 14 method two, and productive rate is 35% (61 mg).
1H NMR (300 MHz, CDCl
3): δ 12.45(s, 1H), 12.39(s, 1H), 11.87(s, 1H), 6.91(s, 1H), 6.08(s, 1H), 4.01(s, 3H), 2.53(s, 3H), 2.42-2.38(m, 7H), 2.28(s, 3H), 2.21(s, 3H), 1.06(t, J = 6.9 Hz, 6H).
13C NMR (75 MHz, CDCl
3): δ 165.5, 146.4, 144.5, 136.2, 135.3, 128.1, 127.4, 126.4, 123.9, 119.8, 117.8, 110.5, 92.4, 58.6, 17.5, 17.3, 15.6, 15.0, 11.8, 9.9. HRMS (EI) Calcd. for C
22H
29N
3O
[M]
+: 351.2311, found 351.2308.
Embodiment 16:
The syntheses and properties of compound III c:
In 50ml round-bottomed flask, under argon shield, add 20 ml ClCH
2cH
2cl, adds pyrroles (0.69 ml, 10 mmol) and 1-chloro-3-methoxyl group-7,9-dimethyl-8-ethyl two pyrroles (102 mg, 0.5 mmol) respectively, and adds POCl fast
3(470 l, 5 mmol), after back flow reaction 8 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 3/1 with ethyl acetate volume ratio) and obtain red-purple powder, productive rate is 41% (60 mg).
1H NMR (300 MHz, CDCl
3): δ 14.01(s, 1H), 12.54(s, 1H), 7.22(s, 1H), 7.02(s, 1H), 6.87(s, 1H), 6.33(s, 1H), 6.06(s, 1H), 3.99(s, 3H), 2.45-2.40(m, 5H), 2.22(s, 3H), 2.18(s, 3H), 1.07(d, J = 7.5 Hz, 3H).
13C NMR (75 MHz, CDCl
3): δ 178.9, 165.5, 137.0, 128.0, 127.1, 124.7, 122.8, 116.6, 113.1, 111.4, 93.0, 58.6, 25.0, 17.4, 14.9, 12.5, 10.0. HRMS (EI) Calcd. for C
18H
21N
3O [M]
+: 295.1685, found 295.1686.
Embodiment 17:
The syntheses and properties of compound IV a:
In 50ml round-bottomed flask, under argon shield, add 20 ml CH
2cl
2, add 2,4-dimethyl pyrrole (2 ml, 20 mmol) and 5-chloro-2-aldehyde pyrroles (129 mg, 1 mmol) respectively, and add the POCl be dissolved in 1 ml methylene dichloride fast
3(940 l, 10 mmol), room temperature reaction 24 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 2/1 with ethyl acetate volume ratio) again and obtain blue solid dyestuff powder, productive rate 48% (63 mg).
1H NMR (300 MHz, CDCl
3): δ 12.95(s, 1H), 12.52(s, 1H), 12.40(s, 1H), 7.11(s, 1H), 6.80(s, 1H), 6.07(s, 1H), 5.92(s, 1H), 2.60(s, 3H), 2.42(s, 3H), 2.35(s, 3H), 2.28(s, 3H).
13C NMR (75 MHz, CDCl
3): δ 149.9, 147.5, 141.5, 138.6, 136.6, 130.9, 129.5, 126.5, 118.5, 118.2, 115.8, 115.5, 114.0, 14.5, 14.2, 13.4, 12.1. HRMS (EI) Calcd. for C
17H
19N
3 [M]
+: 265.1579, found 265.1584.
Embodiment 18:
The syntheses and properties of compound IV b:
In 50ml round-bottomed flask, under argon shield, add 20 ml CH
2cl
2, add 2,4-dimethyl pyrrole (2 ml, 20 mmol) and 5-chloro-2-aldehyde pyrroles (129 mg, 1 mmol) respectively, and add the POCl be dissolved in 1 ml methylene dichloride fast
3(940 l, 10 mmol), back flow reaction 6 h, after reaction terminates, extraction, dry, concentrating under reduced pressure obtains thick product, be separated through column chromatography (stationary phase is silica gel, and elutriant is sherwood oil is the mixed system of 2/1 with ethyl acetate volume ratio) and obtain blue solid dyestuff powder, productive rate is 46% (74 mg).
1H NMR (300 MHz, CDCl
3): δ 12.91(s, 1H), 12.39(s, 1H), 12.29(s, 1H), 7.07(s, 1H), 6.80-6.76(m, 2H), 2.58-2.21(m, 16H), 1.07(s, 6H).
13C NMR (75 MHz, CDCl
3): δ 148.6, 146.8, 137.9, 136.0, 135.8, 129.3, 129.1, 127.6, 126.2, 126.0, 117.9, 117.3, 115.0, 17.4, 17.2, 14.8, 11.8, 9.9. HRMS (EI) Calcd. for C
21H
27N
3 [M]
+ : 321.2205, found 321.2201.
Shown case study on implementation is only for describing summary of the present invention, and do not limit the present invention, technician can implement from main separation in affiliated field.
Claims (2)
1. a preparation method for prodigiosin analogue, is characterized in that:
Raw material is made with 3-halogenated pyrrole or isoindole aldehyde or imine compound and pyrrole derivatives, their mol ratio is 1:10-100, in organic solvent, under magnetic agitation, under temperature 20 DEG C ~ 80 DEG C conditions, under Lewis acid condition, react 1 ~ 24 hour, through extraction, washing, drying, concentrating under reduced pressure, then be separated obtained prodigiosin analogue through silica gel column chromatography;
The structure of described prodigiosin analogue is formula III and IV:
In general formula III, IV,
R
1, R
3, R
5, R
7for CH
3, R
2, R
6for H;
R
1, R
3, R
5, R
7for CH
3, R
2, R
6for CH
2cH
3;
Described pyrrole derivatives is 2,4-dimethyl pyrrole, 2,4-dimethyl-3-N-ethyl pyrrole N-s;
In described raw material, 3-halogenated pyrrole or isoindole aldehyde or imine compound molecular structure are as general formula V, VI:
In general formula V and VI, Y is H, Z is H or methoxyl group, X=Cl, Br, R
8=R
9=C
1-12straight chain or branched-chain alkyl;
Described Lewis acid is selected from POCl
3, CH
3cOOH, CH
3sO
3h, CF
3sO
3h.
2. the preparation method of a kind of prodigiosin analogue according to claim 1, is characterized in that:
Described organic solvent is selected from methylene dichloride, trichloromethane.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210201792.XA CN102731484B (en) | 2012-06-19 | 2012-06-19 | Preparation method for prodigiosins analogue |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210201792.XA CN102731484B (en) | 2012-06-19 | 2012-06-19 | Preparation method for prodigiosins analogue |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102731484A CN102731484A (en) | 2012-10-17 |
CN102731484B true CN102731484B (en) | 2015-01-21 |
Family
ID=46987866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210201792.XA Expired - Fee Related CN102731484B (en) | 2012-06-19 | 2012-06-19 | Preparation method for prodigiosins analogue |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102731484B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103145719B (en) * | 2013-02-27 | 2015-04-29 | 中国科学院化学研究所 | Preparation method of prodigiosin derivative |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1181752A (en) * | 1996-02-15 | 1998-05-13 | 法玛西雅厄普约翰公司 | Process for the prepn. of 2, 2' -bipyrrolyl-pyrromethene (prodigiosins) derivatives |
-
2012
- 2012-06-19 CN CN201210201792.XA patent/CN102731484B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1181752A (en) * | 1996-02-15 | 1998-05-13 | 法玛西雅厄普约翰公司 | Process for the prepn. of 2, 2' -bipyrrolyl-pyrromethene (prodigiosins) derivatives |
Also Published As
Publication number | Publication date |
---|---|
CN102731484A (en) | 2012-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kang et al. | Symmetric containing-PMBP N2O2-donors nickel (II) complexes: Syntheses, structures, Hirshfeld analyses and fluorescent properties | |
Teixidor et al. | Chameleonic Capacity of [3, 3 ‘-Co (1, 2-C2B9H11) 2]-in Coordination. Generation of the Highly Uncommon S (thioether)− Na Bond | |
CN102408452B (en) | Tetrapyridylporphine bridged crossed tetra-palladium complexes, and preparation method and antitumor activity thereof | |
Xu et al. | Structures and Photophysical Properties of Homo-and Heteronuclear Lanthanide (III) Complexes with Bridging 2-Methyl-8-hydroxylquinoline (HMq) in the μ-Phenol Mode | |
CN105541876B (en) | N-heterocyclic carbine metal complex of anthraquinone bridging and preparation method and application | |
CN103274987A (en) | 3,3-disubstituted oxoindole derivative, and synthetic method and application thereof | |
CN110156766A (en) | Preparation method of silver-catalyzed deuterated five-membered aromatic heterocyclic compound | |
Pratihar et al. | Synthesis, characterization, spectral and catalytic activity of tetradentate (NNNO) azo-imine Schiff base copper (II) complexes | |
CN108570076A (en) | A kind of ruthenium complex and its synthetic method and application containing alkynyl | |
Zhao et al. | Syntheses, structural characterizations and properties of 12-MC-4 organotin (IV) metallacrowns:[12-MCRSn (IV) N (shi)-4] and [12-MCRSn (IV) N (Clshi)-4](R= Et, Bu, Ph; H3shi= salicylhydroxamic acid; H3Clshi= 5-chlorosalicylhydroxamic acid) | |
CN102731484B (en) | Preparation method for prodigiosins analogue | |
Adhikary et al. | Synthetic strategy of diflurophosphate-bridged bimetallic N-heterocyclic carbene complexes: Synthesis, structures and photoluminescence of picolyl-substituted alkylbenzimidazolylidene ligands | |
Maurya et al. | Controlled Modification of Triaminoguanidine-Based μ3 Ligands in Multinuclear [VIVO]/[VVO2] Complexes and Their Catalytic Potential in the Synthesis of 2-Amino-3-cyano-4 H-pyrans/4 H-chromenes | |
CN104387790B (en) | A kind of benzindole salt dyestuff of thienyl-containing group and its production and use | |
Liu et al. | Self-discriminating and counteranion-controlled self-assembly: Two heterochiral Cd (II) coordination polymers based on a racemic bis (pyridyl) ligand | |
CN108997341B (en) | Amide-troger's base derivative and its synthesis method and use | |
Zhang et al. | Selective Construction of Trefoil knots and a Molecular Borromean Ring Induced by Steric Hindrance of Thioether Ligands | |
Chen et al. | Coordination of NO 2− ligand to Cu (i) ion in an O, O-bidentate fashion that evolves NO gas upon protonation: a model reaction relevant to the denitrification process | |
Adhikary et al. | Binuclear luminescent silver (I)–N-heterocyclic carbene complex derived from 1-picolyl-3-pyrimidylbenzimidazoliumhexaflurophosphate | |
Asatkar et al. | Thiophene-based salen-type new ligands, their structural aspects and a dimeric Cu (II) complex | |
CN105348146B (en) | Structure, preparation and use of benzil hydrazone-chlorobenzaldehyde bis-Schiff base | |
CN104004508A (en) | Preparation method of conductive mixed metal polymer film material | |
CN102775415B (en) | Synthetic method for porphyrin | |
Sielemann et al. | Selective synthesis of U-shaped terpyridines. Versatile ligands for the preparation of platinum complexes | |
Battisti et al. | Preparation, structure and reactivity of polynuclear Gold (I) phosphanyl alkanethiolates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150121 Termination date: 20150619 |
|
EXPY | Termination of patent right or utility model |